The Legal and Regulatory Landscape

Four categories, not one

People discuss "peptides" as though they were a single regulatory class. They are not. A given molecule can sit in any of four positions, and two compounds sitting in different positions have almost nothing in common legally even if they are chemically adjacent.

1. Approved drugs

A pharmaceutical company has taken the molecule through preclinical work, three phases of human trials, and a regulatory submission; a regulator has reviewed the data and approved it for specified indications at specified doses. Several peptides are in this category: semaglutide and tirzepatide for metabolic indications, tesamorelin, teriparatide, bremelanotide, liraglutide, and others.

These are prescription medicines. Obtaining them means a prescription. Their dossiers contain the most reliable information available anywhere on any peptide: human pharmacokinetics, adverse event rates with denominators, contraindications, interaction data. When a compound has an approved label, read the label. It is free, and it is better than any forum.

2. Compounded preparations

Compounding pharmacies prepare medicines for individual patients: different strength, different form, an allergen removed. In the United States this operates under two regimes: traditional 503A pharmacies compounding per-prescription, and 503B outsourcing facilities operating at larger scale under tighter manufacturing requirements.

Compounding a copy of a commercially available approved drug is generally not permitted. There is a significant exception: while a drug is listed on the regulator's official shortage list, compounders may prepare essentially copies of it. This exception is what produced the enormous compounded-semaglutide market, and when the shortages were declared resolved, the legal basis for that market went with them.¹ The compound did not change. The category did.

The lesson generalises: legal status is a property of circumstances, not of molecules. Something can be lawfully available one quarter and not the next without a single atom moving.

3. "Research chemicals"

This is the category most of the grey market occupies, and it is the one worth understanding precisely, because the label does more work than most buyers realise.

A vial marked For Research Use Only, Not For Human Consumption is not occupying a regulatory category that permits human use under a research exemption. There is no such consumer-facing exemption. The label is a legal posture adopted by the seller. It positions the sale as a supply of laboratory reagents rather than a supply of medicines, which is what keeps the seller outside the regulatory perimeter that governs drugs.

Two consequences follow, and both matter more than the legal question:

• No manufacturing standard applies. An approved drug is made under GMP with regulatory inspection. A research reagent is not. Identity, purity, sterility, endotoxin load, and fill accuracy are whatever the manufacturer decided they should be. This is the entire reason PEP 301 exists.
• No recourse exists. There is no adverse event reporting system, no recall mechanism, no liability chain, and no regulator to complain to. The product was, on paper, never intended to enter a person.

4. Unapproved and restricted

Some peptides have been specifically assessed and specifically restricted. In the United States, the FDA's review of bulk drug substances nominated for compounding placed a number of well-known peptides, BPC-157 among them, into the category judged to present significant safety risks, which removed them from lawful compounding.² Other jurisdictions have made their own determinations: Australia's TGA has scheduled several peptides as prescription-only or prohibited outright, and the UK regulates them under its medicines regime rather than as consumer goods.

A compound being restricted is a signal worth reading. It usually means somebody with access to the data looked, and was not reassured.

Why "it's a supplement" is always wrong

Dietary supplement frameworks cover vitamins, minerals, herbs, amino acids, and similar dietary ingredients. Peptide drugs generally do not qualify. An article that has been authorised for investigation as a new drug is specifically excluded from the definition of a dietary supplement in US law, and that exclusion catches most of the compounds in this field.

So when a product is marketed to you as a peptide supplement, one of two things is true: it is not what it claims to be, or it is being sold outside the framework it claims to be inside. Neither is a good sign about the seller.

The regulatory category is not a technicality attached to the compound. It is the best single predictor of how much anyone actually knows about what is in the vial.

Three practical distinctions

Possession, supply, and importation are different acts

In most jurisdictions these are governed by separate provisions with very different consequences. Personal possession of an unapproved substance is frequently a regulatory matter or no matter at all; supplying it to another person is usually a serious offence; importing it crosses a border and therefore adds a customs regime on top. People routinely reason about all three as though the rules for one applied to the others.

Customs is a separate system

Border agencies enforce their own rules and apply them to shipments regardless of the seller's labelling. Seizure is a routine risk rather than a remote one, and when it happens it is generally an administrative action, with the goods destroyed and a notice issued, rather than a criminal one. It is not the usual outcome: most international shipments in this space do arrive, typically after several weeks. The risk is real, unevenly applied, and higher on international routes than on shipments already inside the destination country. Some jurisdictions operate a limited personal-importation discretion for medicines; it is discretionary, narrow, and not a right.

A second-order consequence is worth naming. A package can be seized and reported without any prosecution following, and that record can still matter later for things that ask about your history with customs, such as trusted-traveller programmes or security clearances. The absence of a criminal charge is not the same as the absence of a consequence.

Sport has its own rulebook entirely

If you compete under a body that follows the World Anti-Doping Code, the WADA Prohibited List governs you, and it is stricter than any national medicines law. Peptide hormones and growth factors are prohibited as a class, and the List includes a catch-all provision covering any pharmacological substance not currently approved for human therapeutic use. Under that provision, a compound's grey-market status is not a loophole. It is the specific thing that prohibits it. Legality and eligibility are unrelated questions.

What you should be able to do now

• Place any compound you encounter into one of the four categories.
• Explain what a "not for human consumption" label does and does not tell you.
• Say why compounded availability can vanish without the compound changing.
• Separate possession, supply, and importation as distinct legal acts.

Module 04 returns to the concrete, and to the place where the most damage actually gets done: arithmetic.